JID Journal Supplement: Tuberculosis Drug Development

Tuberculosis Drug Development: Towards a Critical Path for Developing New Regimes to Treat Tuberculosis

Volume 211 suppl 3 June 15, 2015

Articles:

TB Alliance Drug,TBA-354, enters Phase I Clinical Trials

TB Alliance

TB R&D Update: New treatment strategy using Bedaquiline in combination with heart medication, Verapamil

Researchers at the Center for Tuberculosis Research located at Johns Hopkins University School of Medicine have shown that heart medication, verapamil administered in combination with bedaquline lowers the

2014 Report on Tuberculosis Research Funding Trends, 2005–2013

22 OCTOBER 2014 AT 12:01 a.m. EDT

CONTACT
Mike Frick, Treatment Action Group +1 405.388.4490

2014 WGND Annual Meeting, Barcelona, Oct. 29, 15h-19h

Results of Phase III ReMoxTB Clinical Trial Published

TB R&D Update: Scientists discover a new resistance mechanism to second line drug Bedaquiline

Scientists at Janssen Pharmaceutica have characterized a novel resistance mechanism to Bedaquiline (BDQ), a second line antibiotic for the treatment of MDR-TB. The research study, published in Plos One, showed that tuberculosis resisted BDQ treatment by developing a mechanism to pump the drug out of the cell.

TB R&D Update: Tuberculosis enzyme, isocitrate lyase, grants bacterium protection against antibiotic treatment

A new study published by Dr. Kyu Rhee’s laboratory at the Weill Cornell Medical College details a potential mechanism driving Mycobacterium tuberculosis’ intrinsic resistance to antibiotics.

Panel of TB experts releases report calling for the prioritization of tuberculosis R&D

Kick TB Campaign Expands to Brazil

The Kick TB Campaign is a unique project that uses football (soccer), the World’s most popular sport, to educate and engage young people in the effort to stop the spread of tuberculosis. First inaugurated in South Africa during the 2010 World Cup, Kick TB has expanded to Brazil, the host country of the 2014 World Cup. The goal of Kick TB is to enlist children as “health agents” by teaching them about TB symptoms, diagnosis, prevention, and treatment.